Funny and so polite. Allowed to talk "Cynata", what, with you?
You have demonstrated over and over again that you know nothing about the company you have invested in. With all undue respect, what would you possible have to offer on a company you are not invested in other than mailboxes, computer generated articles, hospital websites that apparently don't lost the CYP trial and things FF never said?
Prove me wrong, please.
Even the entertainment factor of your comments and stiring has gotten repetitive and boring, except when you actually try and share your "research", that's when it gets amusing. Just a shame that on these occasions it is not intended to be.
So, tiny dxxx Tuesday edition.
Generally, I don't give a damn about the SP, but remember last week after the acceptance announcement and you waddled over here,
"Sucks that the CYP SP sank as the MSB SP rocketed up today."
Where is it at now?
So, catch before we move on to Tuesday, little catch up on last night:
any chance you could share with us why Tasly, MSB's Chinese partner for Rexlemestrocel appears to be looking for other alternatives?
https://source.gbihealth.com.cn/news/detail?id=2050322&utm_source=officialAs well as their own product UMSC01:
https://www.taslyus.com/pipeline/umsc01/Are these the early signs of a "It's-not-you-it's-me"-breakup?
Now, Tuesday, remember the famous quote:
"I would much rather take a G0 cell and take it through 20 population doublings, than start with an iPS cell that has divided many times"?
Although two years ahead of where you are currently up to with your thorough MSB research, but given the special guest appearance today, I thought we should talk about another 2018 aka year of the deals announcement:
https://www.sec.gov/Archives/edgar/data/1345099/000156459018014564/meso-ex991_6.htmOh the
-y in this announcement. You have to appreciate a solution for ’OFF-THE-SHELF’ CELL-BASED IMMUNOTHERAPIES that MSB took part in was for a therapy utilising induced Pluripotent Stem Cells:
"Very simply, Cartherics’ technology consists of gene-editing iPSC, establishing stable clones, then deriving potentially limitless numbers of highly functional CAR-iNK cells for ovarian cancer therapies."
https://cartherics.com/news/off-the-shelf-immunotherapy-for-ovarian-cancer/"Potentially limitless" - heard that before in connection with iPSC's before?
Did Cartherics not get the memo about the G0 cell and 20 population doublings?
BTW, this article in the Herald Sun mentions the following:
"The partnership between Melbourne biotech company Cartherics, Hudson Institute of Medical Research, Monash University, Mesoblast and Cell Therapies, plan to start testing their treatments in patients with relapsed ovarian and gastric cancers from next year."
https://heraldsun.com.au/news/victoria/cancerkilling-car-tcell-immunotherapy-to-become-more-accessible-to-patients/news-story/0465ca52f9d85a7df6345117a41e1306The article is dated May 2018. "From next year"? Are we still talking about missed deadlines? Sorry, must have missed your memo if you decided that this topic is now also off the table. I can see why you much rather keep molesting mailboxes in Ireland. Can't blame you. Better talk about CYP and stir the pot here than trying to look into your own investment.
Which one is tinier today? Certainly looks very cold today over at yours.
(20min delay)